Scandinavian Medical Solutions (SMSMED) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
23 Jul, 2026Updated financial guidance
Revenue guidance for FY2024/25 lowered to DKK 200-240m from DKK 240-270m.
EBITDA guidance reduced to DKK 11-15m from DKK 24-29m.
Rationale for guidance adjustment
Geopolitical instability is causing significant volatility in global markets.
Potential import tariffs from Europe to the US are shortening the order book horizon.
Increasing caution among long-term export customers is impacting demand.
Uncertainty regarding the USD exchange rate and customer purchasing power is affecting outlook.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Scandinavian Medical Solutions
- FY2024/25 guidance cut amid tariff, currency, and demand risks; US presence supports resilience.SMSMED
Investor update23 Jul 2026 - Revenue up 20% but profit fell as margin pressure and U.S. expansion weighed on results.SMSMED
H1 24/2523 Jul 2026 - 8% revenue growth and strong Rental/Parts performance, with improved outlook for 2025/26.SMSMED
H2 24/2523 Jul 2026 - Revenue and profit declined amid global headwinds, but cash flow and order backlog improved.SMSMED
H1 25/2623 Jul 2026 - Revenue and EBITDA met targets, with 100% rental utilization and strong U.S. market entry.SMSMED
H2 23/248 Jul 2026